Insoluble particle size distribution testing quantifies subvisible particulate matter in injectable pharmaceuticals, ophthalmic solutions, and medical device extracts, ensuring patient safety and compliance with global pharmacopoeial standards. Performed primarily by light obscuration and microscopic membrane count methods in accordance with USP <788>, EP 2.9.19, JP 6.07, and ChP 0903, the test controls particles at the 10 µm and 25 µm thresholds that cannot be reliably detected by visual inspection. This article reviews the technical principles, sample types, acceptance limits, and practical considerations for accurate subvisible particle analysis.
Technical Overview
Insoluble particulate matter refers to extraneous, mobile, undissolved substances—other than gas bubbles—that are unintentionally present in pharmaceutical products. These particles typically fall within the subvisible size range of approximately 2 µm to 100 µm. Visible particles, generally defined as approximately 50 µm and larger, are controlled through 100% visual inspection per USP <790>, whereas insoluble particle size distribution testing targets the smaller fraction that still presents a measurable clinical risk.
When introduced intravenously, insoluble particles can lodge in pulmonary, cerebral, coronary, or renal capillaries, potentially causing microvascular occlusion, thrombosis, phlebitis, or inflammatory and immune responses. In biologic products, proteinaceous subvisible particles may contribute to immunogenicity. Consequently, quantitative particle control is a mandatory quality attribute for sterile injectable and ophthalmic products worldwide.
Common sources of insoluble particulates include:
- Container-closure components: glass delamination flakes, elastomeric stopper coring, silicone oil droplets, and plastic leachables
- Manufacturing processes: environmental dust, equipment wear debris, and filter or fiber fragments
- Formulation factors: drug crystallization, excipient incompatibility, precipitation, and protein aggregation
- Distribution and handling: mechanical shock, shaking, and temperature excursions during shipping and storage
The governing compendial standards include USP <788> (injections and parenteral infusions), USP <787> (therapeutic protein injections), USP <789> (ophthalmic solutions), EP 2.9.19, JP 6.07, and Chinese Pharmacopoeia ChP 0903. Instrument performance for the primary method is standardized under ISO 21501-2.
Testing Samples
Small-Volume Parenteral Injections (Volumes of 100 mL or Less)
Ampoules, vials, and prefilled syringes containing injectable solutions or reconstituted lyophilized powders. Results are reported as cumulative particle counts per container and compared against per-container limits.
Large-Volume Parenteral Infusions (Volumes Greater Than 100 mL)
Infusion bags and bottles of electrolyte, nutrient, or antibiotic solutions. Because patients receive large administered volumes, results are expressed as particles per mL and evaluated against correspondingly stringent limits.
Biologics and Therapeutic Protein Injections
Monoclonal antibodies, enzymes, and other protein therapeutics are tested per USP <787>, which offers procedural flexibility (reduced sample volume and simplified preparation) to conserve valuable material while maintaining equivalent 10 µm and 25 µm acceptance criteria.
Ophthalmic Solutions and Intraocular Irrigating Solutions
Eye drops and irrigating solutions are evaluated per USP <789>, with an additional counting threshold at 50 µm reflecting the sensitivity of ocular tissues.
Medical Devices and Packaging Components
Rinses, flushes, and extracts of catheters, syringes, tubing sets, filters, and container-closure systems are analyzed to evaluate particulate cleanliness and extractables behavior.
Diluents, Dialysis Solutions, and Sterile Water for Injection
Supporting fluids used in compounding and administration must also demonstrate low intrinsic particulate burdens.
Testing Items
A standard insoluble particle size distribution study delivers the following measurable outputs:
- Cumulative particle counts at the pharmacopoeial thresholds of 10 µm and greater and 25 µm and greater, reported per container or per mL
- Multi-channel size distribution data across extended size bins, for example 2, 5, 10, 15, 20, 25, and 50 µm
- Particle concentration expressed as particles per mL, together with differential channel distributions
- Determination of solution volume per container where limits are expressed on a per-container basis
- Instrument blank and background count verification to confirm low environmental and diluent contribution
- A formal pass or fail conclusion against the applicable compendial acceptance criteria
Testing Methods
Light Obscuration Particle Count Test
Light obscuration (LO) is the preferred first-line method. A portion of the sample is drawn through a calibrated optical sensor; each particle passing through the illuminated sensing zone blocks a fraction of the light beam, generating a voltage pulse proportional to the particle's projected area. Pulse heights are converted to equivalent circular diameters using a calibration curve established with NIST-traceable polystyrene latex sphere standards. The instrument records particle counts across defined size channels and calculates concentrations.
Typical procedure: samples are degassed by brief low-pressure treatment or sonication to remove dissolved air, containers are swirled or inverted gently at least 20 times to resuspend particles without introducing bubbles, and testing is performed in a laminar-flow hood. A minimum of three containers is analyzed; for each measurement at least four consecutive readings are taken, the first is discarded, and the remaining three are averaged.
Light obscuration acceptance limits per USP <788>:
- Small-volume injections: not more than 6000 particles of 10 µm or greater and 600 particles of 25 µm or greater per container
- Large-volume injections: not more than 25 particles of 10 µm or greater and 3 particles of 25 µm or greater per mL
- Ophthalmic solutions per USP <789>: not more than 50 particles per mL at 10 µm, 5 particles per mL at 25 µm, and 2 particles per mL at 50 µm
Microscopic Particle Count Test
The membrane microscopy method serves as the confirmatory or alternative procedure when a product is unsuitable for light obscuration—for example, emulsions, colloids, highly viscous solutions, products with volumes too small for LO sampling, or samples with counts high enough to cause coincidence error. The sample is filtered through a gridded membrane with a retention rating of 1.0 µm or finer, the membrane is dried, and particles are counted at approximately 100× magnification under oblique incident illumination. Particle dimensions are measured along the longest axis using a calibrated ocular micrometer or automated image analysis system.
Microscopic acceptance limits per USP <788>:
- Small-volume injections: not more than 3000 particles of 10 µm or greater and 300 particles of 25 µm or greater per container
- Large-volume injections: not more than 12 particles of 10 µm or greater and 2 particles of 25 µm or greater per mL
Instrument Qualification and Data Quality
Light obscuration systems are qualified per ISO 21501-2, covering size calibration, sensor size resolution, counting accuracy against certified standards, flow rate accuracy, and sample volume accuracy. Test environments must be controlled for background particulates, analysts must be trained, and raw data must be retained in compliance with data integrity expectations. Any preparation artifact, such as air bubbles or silicone oil droplets, should be investigated and distinguished from true product particles.
Orthogonal and Advanced Techniques
For biologics, light obscuration may undercount transparent, amorphous protein particles. Orthogonal tools such as micro-flow imaging (dynamic image analysis), light scattering, and flow cytometry-based methods, guided by USP <1787> and USP <1788>, provide morphology and count data that strengthen the overall particulate control strategy.
Applications
Insoluble particle size distribution testing supports the full product lifecycle:
- Batch release testing of sterile injectables, infusions, and ophthalmic products
- Long-term and accelerated stability programs and shelf-life justification
- Container-closure compatibility studies, including glass delamination and stopper coring risk assessment
- Root-cause investigations of particulate out-of-specification results
- Comparability exercises for process, site, formulation, or packaging changes
- Characterization of subvisible particles in protein therapeutics for regulatory submissions
- Particulate cleanliness evaluation of medical devices and single-use systems
- Supporting data for IND, NDA, ANDA, and BLA filings and post-approval changes
FAQ
What is the difference between visible and subvisible particulate testing?
Visible particulates, generally those of about 50 µm and larger, are controlled through 100% visual inspection of every unit per USP <790>. Insoluble particle size distribution testing is a quantitative laboratory method that counts and sizes the smaller subvisible fraction, primarily at the 10 µm and 25 µm thresholds, on a statistical sample of the batch.
When should the microscopic method be used instead of light obscuration?
Microscopy is required or preferred for emulsions, colloidal systems, viscous products, containers with volumes impractical for LO sampling, and solutions whose counts exceed the sensor's coincidence limits. It is also used to confirm LO failures and to identify particle morphology and probable origin.
How many containers must be tested?
USP <788> requires a minimum of three containers for light obscuration testing of routine release; pooling of multiple small-volume units is permitted when individual container volumes are below the required analytical volume. Regulatory studies and investigations typically expand the sample size for statistical confidence.
Can light obscuration detect protein aggregates in biologics?
LO detects particles based on light blockage and may undercount translucent proteinaceous particles. For biologics, USP <787> governs the count test, and orthogonal methods such as micro-flow imaging are recommended alongside LO to build a complete particle profile.
How are air bubbles and preparation artifacts avoided?
Proper technique includes degassing samples, gentle inversion rather than vigorous shaking, careful priming of tubing, and performing measurements in a low-particulate environment. Unexpected spikes in small-size channels should prompt investigation for bubble interference or silicone contamination.
